Get Permission Hasan, Preethi B L, Kalra, and Kumar M: Taste dyfunction in obese type 2 diabetic individuals


Introduction

Diabetes mellitus and its symptoms were first described in ancient Egypt, around 2000 B.C.1 Over the past few decades, patients with Type 2 Diabetes mellitus have more than doubled globally, making it one of the most important public health challenges worldwide. Type 2 diabetes is strongly associated with obesity. The prevalence of obesity-related diabetes is expected to double to 300 million by 2025.2 The connotation ‘diabesity’, highlights the fact that the majority of diabetic individuals are overweight or obese.3, 4 An increased BMI increases the individuals' mortality risk 7-fold.5 According to the WHO, obesity is the largest global chronic health problem.6 It is estimated that by the year 2030, 60% of the world's population will be overweight or obese.7, 8

An impairment of gustatory function in T2DM patients has been reported in earlier studies. Duration of the disease and poor glycaemic control,9, 10 and obesity might play a causal factor for the same.

Table 1

Concentrations of the taste stimuli used (g/ml) and the allotted scores

Dilution Steps

Score

Sucrose (Sweet)

Sodium chloride (Salty)

Citric acid (Sour)

Quinine hydrochloride (Bitter)

1

1

3

1

2.5

0.02

2

2

1.5

0.5

1.2

0.01

3

3

0.75

0.25

0.6

0.005

4

4

0.38

0.12

0.3

0.0025

5

5

0.19

0.06

0.15

0.0012

Table 2

A comparison of taste scores between Group I and Group II

Taste Scores Mean ± SD

Tastant

Group I

Group II

p value

Sweet

3.9± 0.96

2.34± 1.3

0.000

Salt

4.75± 0.55

3.32± 1.5

0.000

Sour

4.75± 0.55

4± 0.725

0.001

Bitter

3.24± 1.12

2± 1.17

0.002

Materials and Methods

This was a cross-sectional study comprising a sample size of 40. Patients aged 25 to 50 years with T2DM < 5 years duration with HBA1C ≤ 7 were recruited from a tertiary care hospital for the research. They were divided into 2 groups, Group I- with normal weight (BMI of 18.5 to <25) and Group II with grade 1 obesity (BMI of 30 to < 35). The duration of the study was 2 months.

Exclusion criteria comprised of subjects with a past or present history of psychiatric disorders, recent respiratory tract infection, hypothyroidism, chronic kidney or liver disease stage, on sedatives, antibiotics, antiepileptic medications, alcoholics, smokers, pan, tobacco and other substance abusers, pregnant or breastfeeding women and subjects who have contacted COVID-19 in the past six months. Consent was obtained from the Institute’s Review Board. HBA1C levels, anthropometric measurements and BMI were calculated. The triple drop test was used to evaluate gustatory function. Five different concentrations of sweet, salty, sour and bitter tastants were used in dilutions of 50% steps using sucrose, sodium chloride, citric acid, and quinine hydrochloride respectively (Table 1). Samples were presented as drops on the anterior part of tongue, swished in the mouth for ~5 seconds and spit out. Subject was asked to rinse the mouth thoroughly with water in between. Scoring was done depending on the identification of concentrations, “1” being highest, “5” being the lowest concentration.

Statistical analysis

Quantitative variables were analysed using descriptive statistics such as mean and standard deviation, qualitative variables were analysed using frequency and percentage. Student’s t test was used to test the difference in the mean values.

Result

The mean taste scores for the tastants: sweet, salty, sour and bitter in Group I were 3.9± 0.96, 4.75± 0.55, 4.75± 0.55 and 3.24± 1.12 respectively, while the mean taste scores in Group II were 2.34± 1.3, 3.32± 1.5, 4± 0.725 and 2± 1.17 respectively. A significant difference (p < 0.05) was noticed in the taste scores amongst the two groups. This signifies that obese patients with T2DM respond to a higher concentration for the tastants as compared to non-obese T2DM patients. (Table 2)

Discussion

This study provides an assessment of taste sensations perceived by T2DM patients in the Indian population and it supports the findings of previous studies. In a study by Shreya Khera et al it was observed that T2DM patients showed a higher threshold to sweet, salt, sour and bitter tastes.11 Manley KJ et al concluded in their study that a significant impairment in sweet taste sensation occurs in diabetic patients.12

Taste impairment observed in obese T2DM patients can have a negative impact on health and can further deteriorate diabetes. Hypogeusia may cause the already obese diabetics to consume more food and indulge more in hedonic eating. Obesity itself is a risk factor for many diseases esp. in diabetic individuals and it should not progress further. Utilized to advise them to use ingredients that enhance flavours but have low: herbs, spices, potassium chloride, non-nutritive sweeteners and sweet enhancers, in order to limit sodium and sugar intake.

Conclusion

Our study concludes that gustatory impairment for the tastants – sweet, salty, sour, and bitter was observed in obese Type 2 Diabetes mellitus patients having the disease for less than 5 years, though maintaining a fair glycaemic control. This may affect their choices of food items like preference for sweet- tasting food which can exacerbate hyperglycaemia and aggravate obesity. Hypoguesia may also lead to greater intake of salty diet which can escalate the risk of hypertension, renal and heart diseases. Obesity itself is a risk factor for many diseases esp. in diabetic individuals and it should not progress further. It would further decline the quality of life (QOL). Knowledge about Hypogeusia in obese diabetics may be used in dietary counseling. Further, studies with larger sample size should be undertaken to understand how exactly obesity impairs taste sensation.

Source of Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors

Conflicts of Interest

The authors declare no conflicts of interest

References

1 

RA Defronzo E Ferrannini P Zimmet G Alberti International textbook of diabetes mellitusJohn Wiley & SonsUnited States2015

2 

PA Dyson The therapeutics of lifestyle management on obesityDiabetes Obes Metab201012119416

3 

DR Leitner G Frühbeck V Yumuk K Schindler D Micic E Woodward Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies-EASO can lead the wayObes Facts201710548392

4 

P Hossain B Kawar M El Nahas Obesity and diabetes in the developing world—a growing challengeN Engl J Med200735632135

5 

NB Oldridge TE Stump FK Nothwehr DO Clark Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle-and older-age adultsJ Clin Epidemiol200154992834

6 

G Frühbeck H Toplak E Woodward V Yumuk M Maislos JM Oppert Obesity: the gateway to ill health - an EASO position statement on a rising public health, clinical and scientific challenge in EuropeObes Facts20136211720

7 

T Kelly W Yang CS Chen K Reynolds J He Global burden of obesity in 2005 and projections to 2030Int J Obes (Lond)200832914317

8 

MM Finucane GA Stevens MJ Cowan G Danaei JK Lin CJ Paciorek Lancet Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group National, regional, and global trends in body-mass index since 1980:systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participantsLancet2011377976555767

9 

S Wasalathanthri P Hettiarachchi S Prathapan Sweet taste sensitivity in pre-diabetics, diabetics and normoglycemic controls: a comparative cross sectional studyBMC Endocr Disord2014146710.1186/1472-6823-14-67

10 

SM Gondivkar A Indurkar S Degwekar R Bhowate Evaluation of gustatory function in patients with diabetes mellitus type 2Oral Surg Oral Med Oral Pathol Oral Radiol Endod2009108687680

11 

S Khera A Saigal Assessment and evaluation of gustatory functions in patients with diabetes mellitus Type II: A studyIndian J Endocrinol Metab20182222047

12 

KJ Manley RY Haryono RS Keast Taste changes and saliva composition in chronic kidney diseaseRenal Soc Australas J2012825660



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 03-07-2022

Accepted : 13-07-2022


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.ijcap.2022.040


Article Metrics






Article Access statistics

Viewed: 692

PDF Downloaded: 246



Medical Abbreviation List